A Phase I Study Of Weekly Taxotere (Docetaxel) And Gleevec (STI571, Imatinib Mesylate, CGP 57148B) In Locally Advanced Or Metastatic Breast Cancer.

Next Previous
Trial Profile

A Phase I Study Of Weekly Taxotere (Docetaxel) And Gleevec (STI571, Imatinib Mesylate, CGP 57148B) In Locally Advanced Or Metastatic Breast Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 May 2017

At a glance

  • Drugs Docetaxel (Primary) ; Imatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 21 Apr 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
    • 21 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Dec 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top